Patient characteristics
| Characteristic | |
| Age (years) (mean±SD (range)) | 62.26±12.49 (22–83) |
| Women (n (%)) | 25/99 (25.25) |
| High blood pressure (n (%)) | 67/99 (67.68) |
| Atrial fibrillation (n (%)) | 12/99 (12.12) |
| Diabetes (n (%)) | 30/99 (30.30) |
| Initial NIHSS (mean±SD (range)) | 14.41±6.56 (3–30) |
| Occlusion site (n (%)) | |
| M1 occlusion | 45/99 (45.45) |
| M2 occlusion | 10/99 (10.10) |
| Terminal carotid occlusion | 23/99 (23.23) |
| Cervical carotid occlusion | 45/99 (45.45) |
| Cervical carotid stenosis | 18/99 (18.18) |
| Cervical vertebral stenosis | 3/99 (3.03) |
| Cervical vertebral occlusion | 3/99 (3.03) |
| Basilar occlusion | 6/99 (6.06) |
| Tandem occlusion | 52/99 (52.53) |
| Dissection | 16/99 (16.16) |
| Time evolution | |
| Time from onset to endovascular stent treatment (mean±SD (range)) | 441.01±712.55 (25–5880) |
| Unknown onset or wake-up stroke (n (%)) | 11/99 (11.11) |
| Treatment (n (%)) | |
| IV rtPA | 48/99 (48.48) |
| Intracranial stent | 32/99 (32.32) |
| Extracranial stent | 68/99 (68.69) |
| Balloon catheter | 49/99 (49.49) |
| Abciximab doses (mg) (mean±SD (range)) | 9.06±1.72 (6–14) |
| Use of stentriever | 70/99 (70.71) |
| No of passes of stentrievers (mean±SD (range)) | 2.48±1.8 (1–9) |
| Results (n (%)) | |
| Final TICI 2b or 3 | 79/99 (79.8) |
| Time from onset to the end of procedure (min) (mean±SD (range)) | 513.25±740.15 (130–5999) |
| First stenting | 29/99 (29.29) |
| New territory embolus | 8/99 (8.08) |
| Acute stent occlusion | 6/99 (6.06) |
| Vasospasm | 2/99 (2.02) |
| mRS 0–2 at 90 days | 55/99 (55.56) |
IV rtPA, intravenous recombinant tissue plasminogen activator; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; TICI, Thrombolysis in Cerebral Ischemia.